Login / Signup

Evaluation of apremilast in chronic pruritus of unknown origin: A proof-of-concept, phase 2a, open-label, single-arm clinical trial.

Marie ClarkFang WangNancy D BodetBrian S Kim
Published in: Health science reports (2020)
Keyphrases
  • open label
  • clinical trial
  • phase ii
  • phase iii
  • study protocol
  • phase ii study
  • double blind
  • atopic dermatitis
  • squamous cell carcinoma
  • drug induced
  • radiation therapy